Skip to main content
. 2023 Sep 9;6(4):240–252. doi: 10.1093/abt/tbad020

Figure 5.

Figure 5

In vivo efficacy-IMM47 combined with PD-1 antibody (A). In the MC38-hCD24/hPD-L1 tumor cell congenitally transplanted PD-1 transgenic C57BL6 mouse model, IMM47 demonstrated the best anti-tumor activity with a complete response rate of 83%, while the Tislelizumab, IMM2515H (PD-L1 antibody) and IMM2510 (PD-L1 × VEGF BsAb) were 33.33%, 16.7% and 16.7%, respectively, at the same dose. (B) In the MC38-hCD24/hPD-L1 tumor cell congenitally transplanted PD-1 transgenic C57BL/6 mouse model, the combo of IMM47 with Tislelizumab had the best therapeutic effect, and all tumors in mice were eliminated. (C) In the MC38-hCD24/hPD-L1 tumor cell congenitally transplanted PD-1 transgenic C57BL/6 mouse model, the treatment efficacy of the combination of IMM47 and PD-1 antibodies Opdivo and Keytruda was better than that of each individual monoclonal antibody, and the tumor was removed in five of six mice in combination with Opdivo and all six mice in combination with Keytruda. (D) 5 weeks after the discontinuation of combined treatment with IMM47 and Opdivo and Keytruda, reinoculation of the same cancer cells into the mice, tumor growth was quickly and completely eliminated, suggesting tumor-specific immune response has been established.